Kabozantinib  |
| |
| Klinički podaci |
| AHFS/Drugs.com | Monografija |
| Identifikatori |
| CAS broj | 849217-68-1 |
| ATC kod | nije dodeljen |
| DrugBank | DB08875 |
| ChemSpider[1] | 25948202 |
| ChEBI | CHEBI:72317  Y |
| Hemijski podaci |
| Formula | C28H24FN3O5 |
| Mol. masa | 501.51 g mol |
| SMILES | eMolekuli & PubHem |
| InChI |
|---|
InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
Key: ONIQOQHATWINJY-UHFFFAOYSA-N Y | |
| Farmakokinetički podaci |
| Poluvreme eliminacije | 55 h |
| Izlučivanje | Fekalno (54%), renalno (27%). |
| Farmakoinformacioni podaci |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Oralno, oralno |
Kabozantinib (Cometriq) nespecifični inhibitor je tirozinskih kinaza c-Met i VEGFR2, koji redukuje rast tumora, metastazu, i angiogenezu. Odobren je 2012. On se koristi za lečenje metastatčkog medularnog tiroidnog kancera. Kabozantinib može da uzrokuje gastrointestinalne perforacije, fistule, i krvarenje.[2][3][4]
Reference
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Durante C, Russo D, Verrienti A, Filetti S: XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163. PMID 21314233
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
- Nicholas C. Price, Lewis Stevens (1999). Fundamentals of Enzymology: The Cell and Molecular Biology of Catalytic Proteins (Third izd.). USA: Oxford University Press. ISBN 019850229X.
- Eric J. Toone (2006). Advances in Enzymology and Related Areas of Molecular Biology, Protein Evolution (Volume 75 izd.). Wiley-Interscience. ISBN 0471205036.
- Branden C, Tooze J.. Introduction to Protein Structure. New York, NY: Garland Publishing. ISBN: 0-8153-2305-0.
- Irwin H. Segel. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (Book 44 izd.). Wiley Classics Library. ISBN 0471303097.
- William P. Jencks (1987). Catalysis in Chemistry and Enzymology. Dover Publications. ISBN 0486654605.
Spoljašnje veze
 | Portal Medicina |
 | Portal Hemija |
Kabozantinib na Wikimedijinoj ostavi
Y 
